ABLD ABL Texcell Diagnostics SA

2.567USD2.340 EUR · EPA-1.68%Mkt Cap: 41.27M USDP/E: 19.50

ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internation…

Key Statistics

Company
Market Cap41.27M USD
Enterprise Value42.29M USD
Revenue (TTM)12.21M USD
Gross Profit7.26M USD
Net Income (TTM)1.08M USD
Revenue/Share0.53 USD
Last Price2.567 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25
CountryFR
SectorHealthcare
IndustryHealth Information Services
ISINFR001400AHX6
Valuation
P/E (Trailing)19.50
P/E (Forward)—
PEG1.94
EV/EBITDA29.62
EV/Revenue3.46
P/S3.38
P/B4.93
EPS (TTM)0.13 USD
EPS (Forward)—
52W Range
2.3038% of range5.484
52W High5.484 USD
52W Low2.303 USD
Profitability
Gross Margin95.29%
Oper. Margin13.46%
EBITDA Margin11.70%
Profit Margin14.20%
ROE12.93%
ROA7.62%
ROIC3.39%
ROCE3.21%
Growth
Revenue Growth96.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.65M USD
CapEx (TTM)869.40K USD
FCF Margin13.39%
FCF Yield3.96%
Net Debt1.05M USD
Net Debt/EBITDA0.73
Net Debt/FCF0.64
Balance Sheet
Debt/Equity0.29
Current Ratio1.76
Quick Ratio1.30
Book Value/Sh0.52 USD
Cash/Share0.06 USD
Dividends
Fwd Div Rate0.12 USD
Trail. Div Rate0.12 USD
Div. Yield4.58%
5Y Avg Yield—
Payout Ratio89.43%
Ex-Div DateJul 3, 2026
Pay Date—
Splits
Last Split8:1
Split DateMay 18, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.16.08M
Float990.04K
Insiders93.57%
Institutions0.00%
Technical
SMA 502.608 (-1.6%)
SMA 2002.993 (-14.3%)
Beta-0.52
S&P 52W Chg12.00%
Avg Vol (30d)5.05K
Avg Vol (10d)1.61K
Technical Indicators
RSI (14)45.2
MACD-0.0005
MACD Signal0.0046
MACD Hist.-0.0051
BB Upper2.751 USD
BB Middle2.613 USD
BB Lower2.475 USD
BB Width10.56%
ATR (14)0.1049 USD
Vol Ratio (20d)1.25x

About ABL Texcell Diagnostics (EPA: ABLD)

›

ABL Texcell Diagnostics (EPA: ABLD) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 25 employees.

The shares were at 2.340 EUR on 19 November 2026, down 16.4% over 52 weeks. Its 52-week range is 2.100 EUR to 5.000 EUR: the price is 53.2% below the high and 11.4% above the low.

At a market capitalisation of 37.63M EUR, it trades at 19.5 times trailing earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 54% for ABLD. It pays a dividend yielding 4.58% (it pays out 89% of its earnings).

ABL Texcell Diagnostics reports return on equity of 12.9%, an operating margin of 13.5% and revenue up 96.4% year over year.

Its debt exceeds its cash by 955.71K EUR, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health.